What is the main business of Genesum?

The main business activity of Genesum focuses on dispensing chemist in specialised stores.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on August 28, 2014.

Where is the headquarters located?

The headquarters is located at: ul. Żwirki I Wigury 16A, 02-092 Warszawa.

Who is on the management board?

The management board consists of: Grzegorz Bajtała (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 1,000,000 (approx. $270,124).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What was the revenue?

In 2025, the company generated total revenue of USD 1,607,339, representing a decrease of 12.3% compared to 2024.

No, in 2025 the company was not profitable, reporting a net loss of USD 57,608. For comparison, in 2024 the loss was USD 26,200, meaning the company increased its loss by 119.4%.

What is the main operating cost?

The largest operating cost category falls under cost of goods and materials sold. This category amounted to USD 1,111,080 in 2025, representing 69% of all operating expenses.

Genesumsp. z o.o.

Dispensing chemist in specialised stores

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2014-08-28

Share capital

1 000 000,00 PLN

Registered address

ul. Żwirki I Wigury 16A/Biuro 315, 02-092 Warszawa, Poland

Electronic delivery address

AE:PL-22951-66772-TIRTW-24

Financials

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 1.61mMedianUSD 1.75mAverageUSD 5.00m

Net profit

This companyUSD -57.61kMedianUSD 17.49kAverageUSD 85.24k

Operating costs

This companyUSD 1.62mMedianUSD 1.72mAverageUSD 4.85m

Assets

This companyUSD 297.62kMedianUSD 495.38kAverageUSD 1.71m

Industry

Bank accounts

Registered as a VAT taxpayer on 2014-08-28. Active

Erste Bank Polska
13 1090 2590 0000 0001 3005 5326
Erste Bank Polska
38 1090 1883 0000 0001 5253 0251
Erste Bank Polska
41 1090 2590 0000 0001 3005 5307

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Real estate

Type	Amount
Buildings and premises	PLN 2,199PLN 2,199

Secured liabilities

Type	Creditor
Registered pledge	PRIVATBANKA A.S.

Public aid

4 public aid cases recorded, with a total value of $188,485.

Grant date	Purpose	Gross amount	Granting body
Jul 17, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	––	Polski Fundusz Rozwoju S.A.
Jun 20, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	––	Prezes Zakładu Ubezpieczeń Społecznych
May 30, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	––	Prezes Zakładu Ubezpieczeń Społecznych

Tenders

No recorded participation in tenders.

National Health Fund (NFZ) contracts

Genesum has been an NFZ healthcare provider since 2024. In 2025 it is performing 1 contract worth USD 0.00. All its contracts were worth USD 2.51k in total.

NFZ contract value by year (USD)

Type of care	NFZ branch	Contracts	Value in 2025
Programy pilotażowe	mazowieckie	1	USD 0.00

Trademarks

Genesum currently holds no active trademarks with the Polish Patent Office. 2 marks have expired or were not registered. The first mark was filed in 2015.

Mark	Number	Classes	Status	Protected until
APTEKAGOLD.PL(word)	Z.442154	3, 5, 10, 35, 44	Expired	–
AptekaGold	Z.442157	3, 5, 10, 35, 44	Expired	–

Mark	Protected until
APTEKAGOLD.PL(word)	–
AptekaGold	–

Regulatory authorisations

Authority	Type	Status
BDO	BDO register entry	Active

Authorized Representatives

Grzegorz Bajtała – President of the Management Board

Manner of representation

If the management board is a multi-member management board, declarations of will on behalf of the company require the joint action of two members of the management board or one member of the management board jointly with a commercial proxy. In the case of a one-person management board, the company is represented by the President of the Management Board independently.

Ownership

Owner	Shares	Share value	Stake
Megafarm sp. z o.o.	100	$270,124.26	100%

Beneficial owners

Person	Rights

Competitors

Name	Revenue	Website
Cosmedicasp. z o.o.	$49,355,260.75	cosmedica.pl
DR ZdrowieS.A.	$40,415,498.47	drzdrowie.pl
MagmaxS.A.	$4,200,912.15	magmaxsa.pl
Novopharm - Millersp. j.	$2,839,228.36	apteka.zyj-zdrowo.com
MaglowS.A.	$1,356,219.12	maglow.pl
Farmacja Im. O. Klimuszkisp. z o.o.	$1,289,548.20	zyj-zdrowo.com
Nukloversp. z o.o.	$227,479.26	nuklover.com
Massmedsp. z o.o.	$49,747.70	mojoapps.co
DR Farm K. Wenda Zakłady Przemysłowo-Handlowe w Warszawie z Siedzibą w WarszawieS.A.	$2,740.83	kwendasa.pl
Femaherbsp. z o.o.	$655.76	femaherb.com

Change history

Date	Event
2026-08-11	PKD change (Removed: 47.29.Z, 78.30.Z, 86.90.E, 96.09.Z; Added: 47.27.Z, 78.20.Z, 86.99.D, 96.99.Z)
2023-09-22	Address change (Ul. Jana Iii Sobieskiego 1, 44-200, Rybnik → Ul. Żwirki I Wigury 16a/Biuro 315, 02-092, Warszawa)
2023-09-22	PKD change (Removed: 58.14.Z; Added: 47.29.Z)
2022-09-14	Address change (Ul. Pokorna 2/U03, 00-199, Warszawa → Ul. Jana Iii Sobieskiego 1, 44-200, Rybnik)
2022-09-14	PKD change (Removed: 47.29.Z, 47.91.Z, 58.19.Z, 63.12.Z, 82.92.Z, 82.99.Z; Added: 21.20.Z, 52.10.B, 58.14.Z, 78.10.Z, 78.30.Z, 86.90.E)

FAQ

Last updated: 2026-10-07